Tim C. Gupton
North Carolina Certificate #
Tim has over 40 years of public accounting experience. He joined Hughes Pittman & Gupton, LLP in 1992 after 19 years with KPMG Peat Marwick. Tim’s practice was centered on entrepreneurial businesses and their founders that includes owner-managed businesses and investor-financed companies in the Triangle.
Tim was previously with KPMG in Fort Lauderdale, Florida for 19 years, nine years as an audit partner. During his career at KPMG, Tim’s responsibilities included partner-in-charge of the financial institution practice, administrative partner-in-charge of the audit department, associate SEC reviewing partner, and professional practice/quality control partner.
Tim has served as the engagement partner and business advisor to private and public company clients ranging from start-up companies financed by private venture capital to multinational public companies. He has experience auditing companies in a wide range of industries including life sciences, information technology, healthcare services, manufacturing, wholesale distribution, construction, financial institutions, governmental, government contracting, mortgage banking, and real estate.
Tim has served as the start-up CFO for eight biopharmaceutical companies in the Research Triangle.
Tim was the Chairman of the board and Chairman of the Audit Committee for Gentris Corporation, a genomics lab services business with operations in the Research Triangle and Shanghai, which was acquired by Cancer Genetics in 2014.
Tim was the CFO for CoLucid Pharmaceuticals, Inc., a pharmaceutical company developing migraine drugs licensed from Eli Lilly; CoLucid became a public company in 2015.
Tim was a co-founder and served from 1999 to 2010 as CFO for AlphaVax, Inc, a vaccine company based on a new genomic vector technology initially licensed from the University of North Carolina.
Tim was the start-up CFO of Inspire Pharmaceuticals, Inc., a biopharmaceutical company founded in 1995 and became a public company in 2000 and was sold to Merck; the company’s technology originated from the University of North Carolina.
Tim was a co-founder and start-up CFO for SARCO, Inc., a combinatorial chemistry company that was sold to a public company in 1997.
Tim served as the start-up CFO for Trimeris, Inc., a biopharmaceutical company in the Triangle based on technology from Duke University; it was founded in early 1993 and became a public company in 1997.
Tim was a board member and chairman of the audit committee for a small public pharmaceutical development company, Enhance Pharmaceuticals Inc. (formerly Delta and Ardent Pharmaceuticals), based on technology licensed from Burroughs Wellcome.
Tim is a founder and general partner of Research Triangle Ventures, a 2000 venture capital firm focused on early stage investments. The fund is not actively investing in new companies and is focused on managing the remaining portfolio companies to exit. Tim was an advisor to Hatteras HBM Capital, a clinical stage venture fund, during the start-up phase.
Tim is a founder and president of HPG Family Office, LLC, a company providing fiduciary wealth management services for families in the Research Triangle area.
In 1991, Tim was the COO and CFO for John’s Island, a prestigious real estate development in Florida, and the owner’s family office.
B.S., Business Administration, Beta Gamma Sigma
University of North Carolina at Chapel Hill, 1972
Harvard Executive Education Program for KPMG Partners, 1985
American Institute of Certified Public Accountants
North Carolina Association of CPAs
Triangle Community Foundation, Director and Chairman of Audit Committee
North Carolina Bioscience Organization, former Director and former Treasurer
CAM Raleigh, former Director
ibility, Inc., former Director and former Chairman of Audit Committee
Southeast BIO, former Director and Co-Chair of 2011 SEBIO Planning Committee
Council for Entrepreneurial Development
- Former Chairman, 2000/2001
- Former Director and Treasurer
- Chairman of Biotech Roundtable, 1996
- FastTrac Tech Founder and Instructor